Elutia (Nasdaq:ELUT) announced today that it closed the $88 million sale of its bioenvolope technologies to Boston Scientific.
MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) ...
The company has now treated 500,000 patients with its pulsed field ablation system, in a competitive category poised for ...
Hosted on MSN
Boston Scientific Corp (BSX) Secures FDA Labeling Expansion for FARAPULSE Pulsed Field Ablation (PFA) System
Boston Scientific Corporation (NYSE:BSX) is one of Goldman Sachs’ top healthcare stock picks. On July 7, Boston Scientific (NYSE:BSX) saw its shares rise as TD Cowen reaffirmed its Buy rating and $115 ...
WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. AstraZeneca ...
May 28 (Reuters) - Boston Scientific (BSX.N), opens new tab said on Wednesday it has discontinued sales of its heart device in the European Union and will not seek approval in the U.S. and other ...
The FDA has issued a safety alert for several models of Boston Scientific’s Endotak Reliance defibrillation leads after identifying a serious defect linked to 16 deaths and 386 injuries. The leads, ...
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback